Onward Medical N.V. (ONWRY)
OTCMKTS · Delayed Price · Currency is USD
5.10
-0.01 (-0.12%)
Feb 11, 2026, 9:46 AM EST
Onward Medical Revenue
Onward Medical had revenue of 1.19M EUR in the half year ending June 30, 2025, with 27.69% growth. This brings the company's revenue in the last twelve months to 2.72M. In the year 2024, Onward Medical had annual revenue of 1.74M with 226.88% growth.
Revenue (ttm)
2.72M EUR
Revenue Growth
+226.88%
P/S Ratio
69.65
Revenue / Employee
26.48K EUR
Employees
103
Market Cap
222.16M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.74M | 1.21M | 226.88% |
| Dec 31, 2023 | 532.00K | -1.62M | -75.23% |
| Dec 31, 2022 | 2.15M | 749.00K | 53.54% |
| Dec 31, 2021 | 1.40M | 599.00K | 74.88% |
| Dec 31, 2020 | 800.00K | 246.00K | 44.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| South Dakota Soybean Processors, LLC | 484.17M |
| Cardinal Ethanol, LLC | 350.34M |
| National Healthcare Properties | 345.54M |
| Pacific Oak Strategic Opportunity REIT | 88.79M |
| Scope Industries | 77.00M |
| First Northern Community Bancorp | 72.01M |
| Malaga Financial | 45.90M |
| Helios Fairfax Partners | 26.94M |
Onward Medical News
- 8 days ago - ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury - GlobeNewsWire
- 21 days ago - ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement - GlobeNewsWire
- 2 months ago - ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025 - GlobeNewsWire
- 3 months ago - ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use - GlobeNewsWire
- 3 months ago - ONWARD Medical Publishes Closing of Bookbuild Offering - GlobeNewsWire
- 3 months ago - ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase - GlobeNewsWire
- 4 months ago - ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States - GlobeNewsWire
- 4 months ago - Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20 - GlobeNewsWire